JP6898848B2 - 脳転移を治療するための方法 - Google Patents

脳転移を治療するための方法 Download PDF

Info

Publication number
JP6898848B2
JP6898848B2 JP2017515756A JP2017515756A JP6898848B2 JP 6898848 B2 JP6898848 B2 JP 6898848B2 JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017515756 A JP2017515756 A JP 2017515756A JP 6898848 B2 JP6898848 B2 JP 6898848B2
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
subject
gap junction
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534583A (ja
JP2017534583A5 (enExample
Inventor
ジョアン マッサーグ，
ジョアン マッサーグ，
エイドリアン ボワール，
エイドリアン ボワール，
チン チェン，
チン チェン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017534583A publication Critical patent/JP2017534583A/ja
Publication of JP2017534583A5 publication Critical patent/JP2017534583A5/ja
Application granted granted Critical
Publication of JP6898848B2 publication Critical patent/JP6898848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
JP2017515756A 2014-09-19 2015-09-18 脳転移を治療するための方法 Active JP6898848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Publications (3)

Publication Number Publication Date
JP2017534583A JP2017534583A (ja) 2017-11-24
JP2017534583A5 JP2017534583A5 (enExample) 2018-10-25
JP6898848B2 true JP6898848B2 (ja) 2021-07-07

Family

ID=55533931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515756A Active JP6898848B2 (ja) 2014-09-19 2015-09-18 脳転移を治療するための方法

Country Status (7)

Country Link
US (3) US10413522B2 (enExample)
EP (2) EP3193865B1 (enExample)
JP (1) JP6898848B2 (enExample)
CN (1) CN107106544B (enExample)
AU (3) AU2015317330B2 (enExample)
CA (1) CA2961894C (enExample)
WO (1) WO2016044790A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
US11821042B2 (en) * 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
WO2019033041A1 (en) * 2017-08-11 2019-02-14 Board Of Regents, The University Of Texas System TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASES
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
EP4027992A4 (en) * 2019-09-13 2023-11-29 Auckland Uniservices Limited COMPOSITIONS AND METHODS FOR SAVING RETINAL AND CHOROIDAL STRUCTURE AND FUNCTION
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
AU2022414087A1 (en) * 2021-12-14 2024-08-01 Trustees Of Tufts College Use of hyperpolarizing agents alone and in combination with other therapeutic agents for treating cancers including glioblastoma
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
WO2024020491A1 (en) * 2022-07-20 2024-01-25 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
EP4747285A1 (en) * 2023-07-21 2026-05-27 The Board of Regents of the University of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
AU740588B2 (en) 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2004060398A1 (ja) 2002-11-29 2004-07-22 Japan Science And Technology Agency コネキシン２６阻害剤および癌転移抑制剤
EP1653975A4 (en) * 2003-07-31 2006-10-25 Univ Texas COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND / OR PREVENTING CANCER, THE USE OF CANCER OR THE SYMPTOMS OF CANCER
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
WO2008127251A1 (en) 2006-05-05 2008-10-23 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Reversible inhibition of pyramidal gap junction activity
JP2011507860A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
CA2726878A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
WO2010025272A1 (en) * 2008-08-27 2010-03-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
WO2011067607A1 (en) 2009-12-03 2011-06-09 Minster Research Ltd Treatment of infectious diseases
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment
JP2016524593A (ja) * 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
WO2015057862A1 (en) * 2013-10-15 2015-04-23 President And Fellows Of Harvard College Methods and compositions for eradicating leukemic cells
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法

Also Published As

Publication number Publication date
EP3685832A1 (en) 2020-07-29
AU2015317330B2 (en) 2021-01-14
JP2017534583A (ja) 2017-11-24
EP3193865A4 (en) 2018-04-11
US12029717B2 (en) 2024-07-09
AU2015317330A1 (en) 2017-04-13
EP3685832B1 (en) 2023-08-30
WO2016044790A1 (en) 2016-03-24
EP3193865A1 (en) 2017-07-26
CN107106544A (zh) 2017-08-29
CA2961894A1 (en) 2016-03-24
US20200085781A1 (en) 2020-03-19
EP3193865B1 (en) 2019-11-06
AU2023219864A1 (en) 2023-09-14
US20220105069A1 (en) 2022-04-07
NZ730319A (en) 2024-03-22
AU2021202257B2 (en) 2023-05-25
CA2961894C (en) 2023-12-12
US20170258758A1 (en) 2017-09-14
US10413522B2 (en) 2019-09-17
AU2021202257A1 (en) 2021-05-06
CN107106544B (zh) 2021-09-24
US11058665B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
AU2021202257B2 (en) Methods for treating brain metastasis
Fan et al. TSPAN8+ myofibroblastic cancer–associated fibroblasts promote chemoresistance in patients with breast cancer
Caporali et al. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
Jia et al. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Sieve et al. A positive feedback loop between IL-1β, LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages
Cai et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis
Liang et al. miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway
Wang et al. Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC
Wu et al. circFBXO7/miR-96-5p/MTSS1 axis is an important regulator in the Wnt signaling pathway in ovarian cancer
Zhong et al. Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway
Xu et al. RETRACTED: The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis
Subramani et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis
CN103648505B (zh) 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
Feng et al. Rab27A mediated by NF-κB promotes the stemness of colon cancer cells via up-regulation of cytokine secretion
Sheng et al. Exosomal miRNA-92a derived from cancer-associated fibroblasts promote invasion and metastasis in breast cancer by regulating G3BP2
Yang et al. Extracellular vesicle‐packaged miR‐181c‐5p from epithelial ovarian cancer cells promotes M2 polarization of tumor‐associated macrophages via the KAT2B/HOXA10 axis
Chen et al. SNORA73B promotes endometrial cancer progression through targeting MIB1 and regulating host gene RCC1 alternative splicing
Tang et al. Circ-100290 positively regulates angiogenesis induced by conditioned medium of human amnion-derived mesenchymal stem cells through miR-449a/eNOS and miR-449a/VEGFA axes
Yin et al. Ubiquitin-specific peptidase 15 regulates the TFAP4/PCGF1 axis facilitating liver metastasis of colorectal cancer and cell stemness
Huang et al. lncRNA-WAL promotes triple-negative breast cancer aggression by inducing β-catenin nuclear translocation
Ren et al. Fucosyltransferase 8‐Derived Circular RNA Drives M2 Polarization of Macrophages Through ENO1‐TNF Signaling Axis to Promote Lung Cancer Progression
Ma et al. The HNRNPC/CELF2 signaling pathway drives glycolytic reprogramming and mitochondrial dysfunction in drug-resistant acute myeloid leukemia
Taylor et al. Y-box binding protein-1: A neglected target in pediatric brain tumors?
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210611

R150 Certificate of patent or registration of utility model

Ref document number: 6898848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250